Chapter 17 - The Phoenix ProtocolSix months after the federal sentencing, the Montgomery-Thorne Oncology Research Center stood as a beacon of medical innovation.
The fallout from Ethan’s conviction had led to a complete legislative overhaul of how university-affiliated biotech partnerships handled patent disclosures. The new protocol—informally dubbed the "Montgomery Standard" across academic medical circles—ensured that no single investigator could ever again alter institutional IP attribution without multi-tier cryptographic verification.
My office was flooded with sunlight through the high glass windows. On my desk sat the finalized phase-three clinical trial results for our targeted peptide sequence. The survival rates in test subjects were unprecedented, exceeding even our most optimistic projections.
My intercom chimed softly.
"Dr. Montgomery," my administrative assistant’s voice came through. "Dr. Thorne is on line two for you, and the board representatives from Meridian Health Ventures are here in the conference room for the final institutional endowment sign-off."
"Tell them I'll be right down," I said, smiling.
May you like
I stood up, adjusting the cuffs of my crisp white lab coat over my pale blue blouse—a deliberate nod to the past, reclaimed and rewritten entirely on my own terms.
As I walked out into the gleaming hallway, passing posters detailing our life-saving research breakthroughs, I felt a deep, unshakeable sense of peace. The empty chair at the courthouse had once felt like a monument to my failure. Now, looking back, I realized it was the empty space where my old life had died so my real life could begin.
Related Stories
